Psoriasis

33 competing products in clinical development for Psoriasis.

Pipeline by Phase

Pre-clinical1

Phase 12

Phase 212

Phase 2/32

Phase 311

Approved5

All Products (33)

Product	Company	Stage	Status	Hype
Ilumya Injectable Product	Sun Pharmaceutical	Approved	Recruiting	50
Injections of tildrakizumab	Sun Pharmaceutical	Approved	Completed	43
TILDRAKIZUMAB	Sun Pharmaceutical	Approved	Completed	43
Topicort Topical Spray	Sun Pharmaceutical	Approved	Completed	43
Topicort Topical Spray	Sun Pharmaceutical	Approved	Completed	43
Ixekizumab	Eli Lilly	Phase 3	Completed	40
80 mg Ixekizumab Dosing Regimens 1, 2, and 3 + Placebo	Eli Lilly	Phase 3	Completed	40
CT-P43 + Stelara	Celltrion	Phase 3	Completed	40
Tacrolimus Cream	Astellas Pharma	Phase 3	Completed	40
Alefacept	Astellas Pharma	Phase 3	Completed	40
Tacrolimus Cream	Astellas Pharma	Phase 3	Completed	40
Tacrolimus	Astellas Pharma	Phase 3	Completed	40
Desoximetasone Spray 0.25% + placebo comparator	Sun Pharmaceutical	Phase 3	Completed	40
Desoximetasone Spray 0.25% + placebo	Sun Pharmaceutical	Phase 3	Completed	40
KHK4827	Kyowa Kirin	Phase 3	Completed	40
KHK4827	Kyowa Kirin	Phase 3	Completed	40
adalimumab + adalimumab	Eisai	Phase 2/3	Completed	38
Human anti-TNF monoclonal antibody adalimumab/ up to 24 weeks	Eisai	Phase 2/3	Completed	38
Ixekizumab + Placebo	Eli Lilly	Phase 2	Completed	35
Placebo + Baricitinib	Eli Lilly	Phase 2	Completed	35
alefacept	Astellas Pharma	Phase 2	Completed	35
peficitinib + Placebo	Astellas Pharma	Phase 2	Completed	35
ASKP1240 + Placebo	Astellas Pharma	Phase 2	Completed	35
DSXS Topical product	Sun Pharmaceutical	Phase 2	Completed	35
Desoximetasone 0.25% spray	Sun Pharmaceutical	Phase 2	Completed	35
Desoximetasone 0.05% once daily + Desoximetasone 0.05% twice daily + Desoximetasone 0.25% once daily + Desoximetasone 0.25% once daily + Vehicle once daily + Vehicle twice daily	Sun Pharmaceutical	Phase 2	Completed	35
PPC-06 400 mg QD + PPC-06 400 mg BID + PPC-06 600 mg + Placebo	Dr. Reddy's Laboratories	Phase 2	Completed	32
XP23829 400 mg QD + XP 23829 800 mg QD + XP23829 400 mg BID + Placebo	Dr. Reddy's Laboratories	Phase 2	Completed	32
AMG 139	AstraZeneca	Phase 1	Completed	29
Placebo + KHK4827	Kyowa Kirin	Phase 1	Completed	29
LY2525623 Intravenous + LY2525623 Subcutaneous + Placebo Intravenous + Placebo Subcutaneous	Eli Lilly	Phase 2	Terminated	27
VTX958 Dose A + VTX958 Dose B + VTX958 Dose C + VTX958 Dose D + Placebo	Ventyx Biosciences	Phase 2	Terminated	21
Alefacept exposure	Astellas Pharma	Pre-clinical	Terminated	18